Tyra Biosciences (TYRA) Total Non-Current Liabilities (2020 - 2025)
Tyra Biosciences (TYRA) posted Total Non-Current Liabilities of $23.4 million for Q4 2025, up 9.79% on a QoQ basis from $21.3 million in Q3 2025, and up 14.84% year-over-year from $20.4 million in Q4 2024.
Tyra Biosciences (TYRA) Total Non-Current Liabilities (2020 - 2025) Analysis & Trends
Tyra Biosciences' Total Non-Current Liabilities history runs 6 years deep, the most recent figure standing at $23.4 million for Q4 2025.
- Quarterly Total Non-Current Liabilities rose 14.84% year-over-year to $23.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $23.4 million (up 14.84% YoY) and the FY2025 annual result came in at $23.4 million, up 14.84% from the prior year.
- Total Non-Current Liabilities was $23.4 million for Q4 2025 at Tyra Biosciences, up from $21.3 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $23.4 million in Q4 2025 and bottomed at $4.6 million in Q4 2021.
- A 5-year average of $14.0 million and a median of $15.5 million in 2023 frame the typical range for Total Non-Current Liabilities.
- Peak annual rise in Total Non-Current Liabilities reached 163.34% in 2023, while the deepest fall reached 18.15% in 2023.
- Tyra Biosciences' Total Non-Current Liabilities stood at $4.6 million in 2021, then jumped by 78.01% to $8.2 million in 2022, then jumped by 163.34% to $21.5 million in 2023, then slipped by 5.31% to $20.4 million in 2024, then advanced by 14.84% to $23.4 million in 2025.
- Business Quant data shows TYRA's Total Non-Current Liabilities at $23.4 million in Q4 2025, $21.3 million in Q3 2025, and $19.4 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 4.45 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 110.28 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.98 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 949,738.67 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 5.87 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 7.32 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 40.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 746.94 Mn |
| 10 | Tyra Biosciences | 1.90 Bn | 1.90 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 23.43 Mn |
| Sep 30, 2025 | 21.34 Mn |
| Jun 30, 2025 | 19.35 Mn |
| Mar 31, 2025 | 19.94 Mn |
| Dec 31, 2024 | 20.40 Mn |
| Sep 30, 2024 | 18.29 Mn |
| Jun 30, 2024 | 16.40 Mn |
| Mar 31, 2024 | 14.83 Mn |
| Dec 31, 2023 | 21.55 Mn |
| Sep 30, 2023 | 16.11 Mn |
| Jun 30, 2023 | 11.33 Mn |
| Mar 31, 2023 | 6.13 Mn |
| Dec 31, 2022 | 8.18 Mn |
| Sep 30, 2022 | 8.00 Mn |
| Jun 30, 2022 | 8.00 Mn |
| Mar 31, 2022 | 7.48 Mn |
| Dec 31, 2021 | 4.60 Mn |
| Sep 30, 2021 | 5.81 Mn |
| Dec 31, 2020 | 1.86 Mn |